B
Bull
Bull · 25%PRQR
$2.08
Szenariopreis
$2.120
-0.010 (-0.47%)Zum Schluss
Loading chart…
- High
- 2.140
- Open
- 2.140
- VWAP
- 2.11
- Vol
- 569.32K
- Mkt Cap
- 134.74M
- Low
- 2.080
- Amount
- 1.20M
- EV/EBITDA, TTM
- -13.67
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
AI analysis of ProQR Therapeutics NV (PRQR)
buyProQR Therapeutics is a good buy right now, trading at $2.29 with a recent analyst price target of $8 from BofA, indicating a potential upside of over 250%. Additionally, the stock has a strong RSI of 60.6, suggesting it is not overbought. The main risk is the negative net income of -13,383,000 EUR in Q1 2026, which reflects ongoing financial challenges.
Analyst Ratings (4)
+308.96% upside
Buy
3 Buy
1 Hold
0 Sell
Current: 2.12
Tief
5.00
Durchschnitt
8.67
Hoch
12.00
Raymond James
Strong Buy
$10
2026-06-26
Raymond James
2026-06-26
Kursziel
$10
Strong Buy
JonesResearch
Buy
$10
2026-06-26
JonesResearch
2026-06-26
Kursziel
$10
Buy
Chardan
Buy
$3
2026-06-25
Chardan
2026-06-25
Kursziel
$3
Buy
Oppenheimer
Outperform
$9
2026-03-12
Oppenheimer
2026-03-12
Kursziel
$9
Outperform
Evercore ISI
Outperform
$5
2025-07-11
Evercore ISI
2025-07-11
Kursziel
$5
Outperform
Bewertungskennzahlen
The current forward P/E ratio for ProQR Therapeutics NV (PRQR) is 0.00, compared to its 5-year average forward P/E of -5.13.
Alphio AI Price Scenarios for PRQR
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding PRQR
Event-Zeitleiste
News
8.506-26NASDAQ.COMProQR Announces Underwritten Direct Offering, Shares Drop 20%
8.506-25seekingalphaProQR Therapeutics Prices $50M Direct Offering of 27.6M Shares
- 9.006-25seekingalpha
ProQR Therapeutics Reports Positive Phase 1 Data for AX-0810
- 9.006-25NASDAQ.COM
ProQR Reports Positive Data from AX-0810 Phase 1 Study
9.006-25NewsfilterPositive Phase 1 Study Results for AX-0810 Indicate Significant NTCP Modulation
PRQR FAQ — answered by Alphio AI
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
ProQR Therapeutics is a good buy right now, trading at $2.29 with a recent analyst price target of $8 from BofA, indicating a potential upside of over 250%. Additionally, the stock has a strong RSI of 60.6, suggesting it is not overbought. The main risk is the negative net income of -13,383,000 EUR in Q1 2026, which reflects ongoing financial challenges.
4 analysts cover PRQR: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 8.67.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.